Rimegepant｜Migraine｜HongKong DengYue Medicine

Rimegepant Application Scope

Indications:

• Acute treatment of migraine with or without aura in adults.
• Preventive treatment of episodic migraine (≥4 migraine attacks per month) in adults.

Rimegepant Characteristics

Ingredients:

• Active ingredient: Rimegepant sulfate.
• Inactive ingredients: Gelatin, mannitol, sucralose, and peppermint flavor (for the orally disintegrating tablet).

Properties:

• Mechanism of action: Selective antagonist of the calcitonin gene-related peptide (CGRP) receptor, inhibiting neurogenic inflammation and vasodilation associated with migraine.
• Bioavailability: ~64% absolute oral bioavailability, peak plasma concentration reached in ~1.5 hours.

Specification:

• Dosage form: Orally disintegrating tablet (ODT).
• Strength: 75 mg per tablet.

Packaging Specification:

• Typically supplied in blister packs of 8 tablets.

Storage:

• Store at 20°C–25°C (excursions permitted between 15°C–30°C).

Expiry Date:

• 24 months from the date of manufacture.

Executive Standard:

• Complies with FDA and NMPA regulatory standards.

Approval Number:

• FDA approval (Nurtec ODT) in 2020; NMPA approval (China) in 2024.

Date of Revision:

• Updated prescribing information as of 2024 (latest revisions).

Manufacturer:

• Brand name (Nurtec ODT): Originally developed by Biohaven, now marketed by Pfizer.

Guidelines For The Use Of Rimegepant

Dosage and Administration:

• Acute treatment: 75 mg orally as needed, max 1 dose in 24 hours.
• Preventive treatment: 75 mg every other day.
• Administration: Place tablet on the tongue; it dissolves without water.

Adverse Reactions:

• Common: Nausea (1.2%), abdominal pain, dyspepsia.
• Serious but rare: Hypersensitivity reactions (rash, difficulty breathing).

Contraindications:

• Hypersensitivity to rimegepant or any excipients.
• Severe hepatic impairment (Child-Pugh C).

Precautions:

• Hepatic impairment: Avoid in severe liver disease.
• Renal impairment: No dose adjustment needed, but avoid in end-stage renal disease.
• Pregnancy/Lactation: Limited data; use only if clearly needed.

Rimegepant Interactions

Drug Interactions:

• Strong CYP3A4 inhibitors (e.g., ketoconazole): Avoid concurrent use.
• Strong CYP3A4 inducers (e.g., rifampin): May reduce efficacy.
• P-gp/BCRP inhibitors (e.g., cyclosporine): Monitor for increased rimegepant exposure.

 

Note:

• If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
• It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.